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Recent researches suggest that there may be a relationship
between neurohormones, immune status and cancer. The
observations, on the basis of which this experiment was
undertaken, run briefly as follows: tumour onset has been
shown to be associated with changes in neuroendocrine func-
tions. These include brain neurotransmitter concentrations
(Vinnitsky, 1988), pineal activity and opioid peptide secretion
(Esposti et al., 1988). Melatonin (MLT) represents the best
understood hormone produced by the pineal gland, and it
has a particular importance in the modulation of brain
neurotransmitter pathways (Anton-Tay et al., 1968). MLT,
therefore, has been proposed as a means of monitoring the
neuroendocrine status during cancer development (Ebels,
1980).
Several experimental observations have shown that both
the pineal hormone MLT (Buswell, 1975) and endogenous
opioid peptides (Morley et al., 1985) may influence cancer
growth by regulating cell proliferation and immune reactions.
In particular, MLT has been seen to induce the expression of
interleukin-2 (IL-2) receptors on immune cells (Cattaneo et
al., 1988) and to synergise with IL-2 in the generation of
LAK cells in some conditions (Maestroni et al., 1988).
Because of the well documented importance of IL-2 in the
activation of an effective antitumour immune response
(Grimm et al., 1982), its interactions with neurohormones
could play a role in regulating host antitumour biological
response. In the light of this possibility, an investigation of
the relationship between IL-2, MLT and the opioid peptide
P-endorphin (END) was undertaken in patients with solid
neoplasms. The experiment designed to develop an under-
standing of these findings was conducted from April 1989 to
June 1989 in 84 consecutive patients (47 men, 37 women;
median age 54 years, range 32-73) with histologically proven
solid neoplasm. Tumour types were as follows: breast, 26;
lung, 32 (non-small cell, 21; small cell, 11); colon, 12;
stomach, 8; uterine cervix, 6. Distant organ metastases were
present in 45 patients. Peripheral venous blood samples were
collected from each patient during the morning. Control
samples were drawn from 58 age- and sex-matched healthy
subjects, chosen among nursing staff and healthy blood
donors. Serum levels of MLT, END and IL-2 were detected
in every blood sample. IL-2 concentrations were measured by
RIA method in accord with that previously described by
Caderas (1986), using commercial kits (Advanced Magnetics
Inc., Cambridge, MA). The assay uses an '251-labelled
monoclonal antibody and a rabbit polyclonal antibody to
human IL-2. IL-2 levels are expressed as mUml-', where
1 U is defined as the amount of IL-2 required for half
maximal tritiated-thymidine incorporation by IL-2-
dependent CTLL cells. Sensitivity of the assay was
60 mU ml-'. Intraassay and interassay coefficients of varia-
tion were 6% and 9%, respectively. MLT levels were
measured with a double antibody RIA method using com-
mercial kits (Euro-Diagnostics, Apeldoorn-Holland). END
values were also measured with a RIA method using com-
mercially available kits (Nichols Institute Diagnostics, San
Juan Capistrano, CA). All samples were measured in dupli-
cate in a single assay. The data were reported as mean ± s.e.,
and the results were statistically analysed by the Student's
t-test.
Normal values (95% confidence limits) seen in healthy
controls were as follows: MLT, 4-30 pg ml-'; END,
6-90 pg ml-'; IL-2, 110-1500 mU ml-'. Elevated concentra-
tions of MLT were found in 25/84 (31%) cancer patients,
while END values were within the normal range in all cases.
MLT mean serum levels were significantly higher in cancer
patients than in controls (P <0.01), while no significant
difference was seen in END mean circulating levels. Serum
mean concentrations of IL-2 were lower in cancer patients
than in controls, without, however, any statistical difference;
on the contrary, by considering IL-2 secretion in relation to
the clinical stage, metastatic cancer patients showed
significantly lower mean levels of IL-2 in respect to those
observed either in the normal subjects or in non-metastatic
cancer patients (P <0.05). Patients with elevated concen-
trations of MLT showed significantly higher mean levels of
IL-2 than patients with normal MLT values (P <0.05);
moreover, END mean levels were lower in patients with high
levels of MLT than in those with normal values, but this
difference was not statistically significant. Serum mean levels
of IL-2, MLT and END observed in cancer patients and in
controls are reported in Table I.
This study accords with the in vitro results previously
reported by other authors (Nakayama et al., 1983), would
suggest that metastatic dissemination may be associated with
a reduced IL-2 secretion in human solid neoplasms. The
mechanisms responsible for the decreased IL-2 production in
cancer have still to be understood. Since recent experimental
observations have showed that IL-2 secretion is influenced by
a neuroendocrine control, it is not possible to exclude that
the low IL-2 production in cancer may depend, at least in
part, on alterations in the psychoneuroendocrine control of
the immunity. Moreover, the results of this study show that
an increased MLT secretion is associated with higher levels
of IL-2 in respect to those found in patients, who do not
show any hyperfunction of the pineal gland; this finding
would suggest that the enhanced MLT secretion may
counteract tumour growth by modulating host anti-tumour
biological response. However, the associations between high
levels of MLT and of IL-2 are not necessarily representative
of a causative link. In vitro studies to test the effects of MLT
on IL-2-dependent immune response will be required to bet-
ter understand the role of the pineal hormone and to verify
whether MLT may directly influence or not IL-2 production
and activity. Our preliminary in vitro data would suggest a
stimulatory role of MLT on some IL-2-dependent immune
reactions (Cattaneo et al., 1988). Moreover, it has to be
remarked that the present study was limited to the detection
of the only daily levels of the pineal hormone. Therefore,
further studies will be needed to better define which relation
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Table I Serum levels (mean ± s.e.) of IL-2, melatonin and beta-endorphin in
patients with solid neoplasms and in healthy subjects
IL-2 Melatonin Endorphin
Cases n (mUml') (pgml') (pgm1')
Healthy subjects 58 389±48 18 3 36 6
Cancer patients 84 294 ± 51 43 ± 6a 44± 7
Non-metastatic patients 38 432 63 49± 5 39± 6
Metastatic patients 46 213 ± 36b 28 ± 8 47 9
Patients with high melatonin 25 486 ± 39c 57 ± 8d 28 ± 5
Patients with normal melatonin 59 297 ±47 21 ± 5 46± 7
ap<0.01 vs healthy subjects. bp<0.05 vs non-metastatic cancer patients and
healthy subjects. CP <0.05 vs patients with normal melatonin values. dp <0.01
vs patients with melatonin within the normal range.
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